Obstructive Sleep Apnea (OSA)
Obstructive sleep apnea (OSA)—also referred to as obstructive sleep apnea-hypopnea—is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. It is the most common type of sleep-disordered breathing and is characterized by recurrent episodes of upper airway collapse during sleep.  These episodes are associated with recurrent oxyhemoglobin desaturations and arousals from sleep.
OSA that is associated with excessive daytime sleepiness is commonly called obstructive sleep apnea syndrome—also referred to as obstructive sleep apnea-hypopnea syndrome.
The image below illustrates the sleep-related disordered breathing continuum ranging from simple snoring to OSA.
Generally, symptoms of OSA begin insidiously and are often present for years before the patient is referred for evaluation.
Nocturnal symptoms may include the following:
Snoring, usually loud, habitual, and bothersome to others
Witnessed apneas, which often interrupt the snoring and end with a snort
Gasping and choking sensations that arouse the patient from sleep, though in a very low proportion relative to the number of apneas they experience
Insomnia; restless sleep, with patients often experiencing frequent arousals and tossing or turning during the night
Daytime symptoms may include the following:
Nonrestorative sleep (ie, “waking up as tired as when they went to bed”)
Morning headache, dry or sore throat
Excessive daytime sleepiness that usually begins during quiet activities (eg, reading, watching television); as the severity worsens, patients begin to feel sleepy during activities that generally require alertness (eg, school, work, driving)
Cognitive deficits; memory and intellectual impairment (short-term memory, concentration)
Personality and mood changes, including depression and anxiety
Sexual dysfunction, including impotence and decreased libido
See Clinical Presentation for more detail.
In general, the physical examination is normal in patients with OSA, aside from the presence of obesity (body mass index: >30 kg/m2), an enlarged neck circumference (men: >43 cm [17 in]; women: >37 cm [15 in]), and hypertension.
Evaluate the upper airway in all patients, particularly in nonobese adults with symptoms consistent with OSA.
Examination findings may include the following:
Abnormal (increased) Mallampati score: Identifies risk for difficult tracheal intubation
Narrowing of the lateral airway walls: Independent predictor of the presence of obstructive sleep apnea in men but not women
Enlarged (ie, “kissing”) tonsils (3+ to 4+)
Retrognathia or micrognathia
Large degree of overjet
High-arched hard palate
Systemic arterial hypertension: Present in about 50% of obstructive sleep apnea cases
Congestive heart failure
Type 2 diabetes mellitus
An overnight sleep study, or polysomnography, is required to diagnose OSA.
Routine laboratory tests, however, are usually not helpful in OSA unless a specific indication is present. Pulmonary function tests are not indicated to make a diagnosis of, or treatment plan for, OSA alone. The standard indications for such testing apply to all patients, with or without OSA.
Obtain a thyrotropin test on any patient with possible OSA who has other signs or symptoms of hypothyroidism, particularly in elderly individuals.
AASM standards and guidelines for diagnostic polysomnography
The American Academy of Sleep Medicine guidelines for the indications and performance of polysomnography include the following  :
Sleep stages are recorded via an electroencephalogram, electro-oculogram, and chin electromyogram
Heart rhythm is monitored with a single-lead electrocardiogram
Leg movements are recorded via an anterior tibialis electromyogram
Breathing is monitored, including airflow at the nose and mouth (using both a thermal sensor and a nasal pressure transducer), effort (using inductance plethysmography), and oxygen saturation
The breathing pattern is analyzed for the presence of apneas and hypopneas (as per definitions standardized by the American Academy of Sleep Medicine)
See Workup for more detail.
Treatment of OSA partly depends on the patients’ severity of sleep-disordered breathing. Those with mild apnea have more options, whereas people with moderate to severe apnea should be treated with nasal continuous positive airway pressure (CPAP).
Conservative therapy and prevention
The following conservative measures may help manage or prevent OSA:
Restriction of body positions during sleep (avoid supine position)
Sleeping in an upright position for markedly obese patients
Avoiding smoking; smoking cessation
Avoiding alcohol and other sedatives (particularly 4-6 hours before bedtime)
Avoiding sleep deprivation
Mechanical measures used in the treatment of OSA include the following:
Nasal CPAP: Standard treatment option
Bilevel positive airway pressure
Oral appliance therapy
Medications are generally not a part of the primary treatment recommendations for OSA. However, central nervous system stimulants such as modafinil and armodafinil have been used adjunctively in the management of this condition.
Surgical intervention for OSA includes, but is not limited to, the following:
Craniofacial reconstruction with advancement of tongue or maxillomandibular bones
Obstructive sleep apnea (OSA)—also referred to as obstructive sleep apnea-hypopnea (OSAH)—is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. It is the most common type of sleep-disordered breathing (SDB) and is characterized by recurrent episodes of upper airway (UA) collapse during sleep.  These episodes are associated with recurrent oxyhemoglobin desaturations and arousals from sleep.
OSA associated with excessive daytime sleepiness (EDS) is commonly called obstructive sleep apnea syndrome (OSAS)—also referred to as obstructive sleep apnea-hypopnea syndrome (OSAHS). Despite being a common disease, OSAS is underrecognized by most primary care physicians in the United States; an estimated 80% of Americans with OSAS are not diagnosed. 
Apnea may occur hundreds of times nightly, 1-2 times per minute, in patients with severe OSA, and it is often accompanied by wide swings in heart rate, a precipitous decrease in oxygen saturation, and brief electroencephalographic (EEG) arousals concomitant with stertorous breathing sounds as a bolus of air is exhaled when the airway reopens.
The cardinal symptoms of sleep apnea include the “3 S ’s”: S noring, S leepiness, and S ignificant-other report of sleep apnea episodes. This helpful mnemonic has proven to be valuable in teaching residents to be sensitive in the identification and appropriate referral of these patients for further study.
Also helpful is if patients’ spouses or others who are close to them can attend visits. Often, sleepers are unaware that they have OSA and may in fact regard themselves as “good sleepers” because they “can sleep anytime, anywhere” (eg, in the physician’s waiting room, in traffic, in class, at his or her office). Sleepiness is one of the potentially most morbid symptoms of sleep apnea, owing to the accidents that can occur as a result of it.
OSA is a very important diagnosis for physicians to consider because of its strong association with and potential cause of the most debilitating medical conditions, including hypertension, cardiovascular disease, coronary artery disease, insulin-resistance diabetes, depression, and, as mentioned, sleepiness-related accidents.
Go to Childhood Sleep Apnea for complete information on this topic.
For the purposes of the following discussion, it is useful to define the breathing events being examined. These breathing events include the following:
Respiratory effort–related arousal (RERA)
Apnea is defined by the American Academy of Sleep Medicine (AASM) as the cessation of airflow for at least 10 seconds.  Apnea may last for 30 seconds or even longer.
The most recent guidelines from the American Academy of Sleep Medicine (AASM Weekly Update 9/26/2013) updated the definitions of the terms for scoring hypopneas (recommended and acceptable), as follows:
Recommended: Score a respiratory event as a hypopnea if all of the following criteria are met: (1) peak signal excursions drop by at least 30% of pre-event baseline using nasal pressure (diagnostic study), positive airway pressure device flow (titration study), or an alternative hypopnea sensor (diagnostic study); (2) duration of the at least 30% drop in signal excursion is 10 or more seconds; and (3) there is 3% or greater oxygen desaturation from pre-event baseline and/or the event is associated with an arousal.
Acceptable: Score a respiratory event as a hypopnea if all of the following criteria are met: (1) the peak signal excursions drop by 30% or greater of pre-event baseline using nasal pressure (diagnostic study), positive airway pressure device flow (titration study), or an alternative hypopnea sensor (diagnostic study); (2) the duration of the at least 30% drop in signal excursion is 10 or more seconds; and (3) there is 4% or greater oxygen desaturation from pre-event baseline.
An RERA is an event characterized by increasing respiratory effort for 10 seconds or longer leading to an arousal from sleep but one that does not fulfill the criteria for a hypopnea or apnea. The criterion standard to measure RERAs is esophageal manometry, as the AASM recommends. However, esophageal manometry is uncomfortable for patients and impractical to use in most sleep centers.
A reliable and valid way to measure RERAs is with the use of a nasal cannula and pressure transducer. Results obtained with this transducer are reliable. With regard to the diagnosis of OSA, this method does not differ from esophageal manometry in a clinically significant manner. With either method, the respiratory disturbance index (RDI) is greater than 5 and the normal RDI cutoff is greater than 15.
Obstructive apneas and hypopneas are typically distinguished from central events. Obstructive events are characterized by continued thoracoabdominal effort in the setting of partial or complete airflow cessation, central events by lack of thoracoabdominal effort in this setting. Mixed events have both obstructive and central features. They generally begin without thoracoabdominal effort and end with several thoracoabdominal efforts in breathing; they are tabulated in the obstructive apnea index.
A sleep-related breathing disorder (SRBD) continuum has been described and is supported by research.  OSA can be thought of as occupying a range of this continuum.
The idea of the SRBD continuum was first described by Elio Lugaresi: “There is a continuum of intermediate clinical conditions between trivial snoring and the most severe forms of OSAS (which we prefer to call heavy snorers disease). This fact should be taken into consideration for any meaningful approach to the clinical problems posed by snoring. Many issues, however, remain unsettled.” 
The SRBD continuum suggests that snoring is the initial presenting symptom, and it increases in severity over time and it increases in association with medical disorders that may serve to exacerbate the disorder, such as obesity. Snoring has a constellation of pathophysiological effects. 
As the disease progresses, SRBD patients begin to develop increased UA resistance that results in a new hallmark symptom: sleepiness. Sleepiness is caused by increased arousals from sleep.  This syndrome has been described as the UA resistance syndrome (UARS). UARS patients are not hypoxic, and hypoxia does not explain why they are sleepy, nor can sleep stage percentages or other polysomnography (PSG) variables. The SRBD continuum predicts that over time, a UARS patient develops OSA, if untreated (see the image below).
OSA has as its hallmark symptoms snoring, sleepiness, spouse apnea report, and hypoxia. The SRBD continuum suggests that over time, untreated OSA may hasten death through heart disease, hypertension, stroke, myocardial infarction, heart failure, cardiac arrhythmia, diabetes, metabolic syndrome, or vehicular or other accident due to sleepiness or other behavioral effects noted.
Conceptually, the UA is a compliant tube and, therefore, is subject to collapse.  OSA is caused by soft tissue collapse in the pharynx.
Transmural pressure is the difference between intraluminal pressure and the surrounding tissue pressure. If transmural pressure decreases, the cross-sectional area of the pharynx decreases. If this pressure passes a critical point, pharyngeal closing pressure is reached. Exceeding pharyngeal critical pressure (Pcrit) causes a juggernaut of tissues collapsing inward. The airway is obstructed. Until forces change transmural pressure to a net tissue force that is less than Pcrit, the airway remains obstructed. OSA duration is equal to the time that Pcrit is exceeded.
Most patients with OSA demonstrate upper airway obstruction at either the level of the soft palate (ie, nasopharynx) or the level of the tongue (ie, oropharynx). Research indicates that both anatomic and neuromuscular factors are important.
Anatomic factors (eg, enlarged tonsils; volume of the tongue, soft tissue, or lateral pharyngeal walls); length of the soft palate; abnormal positioning of the maxilla and mandible) may each contribute to a decrease in the cross-sectional area of the upper airway and/or increase the pressure surrounding the airway, both of which predispose the airway to collapse. [10, 11] Note that in adults, it is very rare for enlarged tonsils and adenoids to be a cause of OSA. Removing the enlarged adenoids and tonsils alone rarely is an effective surgical remedy; in children, about 80% who have have OSA are cured with the removal of enlarged adenoids and tonsils. There is often a misconception that enlarged adenoids and tonsils may be a singular cause of OSA in both children and adults, but this is not true.
Neuromuscular activity in the UA, including reflex activity, decreases with sleep, and this decrease may be more pronounced in patients with OSA. [12, 13, 14] Reduced ventilatory motor output to upper airway muscles is believed to be the critical initiating event leading to UA obstruction; this effect is most pronounced in patients with a UA predisposed to collapse for anatomical reasons.
Central breathing instability is a well-established factor contributing to the development of central sleep apnea (CSA), particularly in patients with severe congestive heart failure (CHF). [15, 16, 17] Evidence also indicates that central breathing instability contributes to the development of OSAS.
First, evidence of UA obstruction in the absence of ventilatory motor output (central sleep apnea) has been observed.  Second, reduction in pharyngeal dilator activity has been associated with periodic breathing [19, 20, 21] and hypocapnia in subjects with evidence of inspiratory flow limitation.  Third, men have been shown to be more susceptible to the development of CSA and less responsive to carbon dioxide than women are,  a result consistent with the greater prevalence of OSAS in men than in women.
Both static factors and dynamic factors are involved in the development of OSA. Static factors include surface adhesive forces, neck and jaw posture, tracheal tug, and gravity. Any anatomic feature that decreases the size of the pharynx (eg, retrognathia) increases the likelihood of OSA. Gravitational forces are felt simply by tilting one’s head back to where the retroposition of the tongue and soft palate reduce the pharyngeal space. For most patients, OSA worsens in the supine sleeping position.
An important static factor that has been found is the reduced diameter of the pharyngeal airway in wakefulness in OSA patients compared with non-OSA patients. In the absence of craniofacial abnormalities, the soft palate, tongue, parapharyngeal fat pads, and lateral pharyngeal walls are enlarged in OSA patients versus non-OSA patients.
Dynamic factors include nasal and pharyngeal airway resistance, the Bernoulli effect, and dynamic adherence.
The Bernoulli effect plays an important dynamic role in OSA pathophysiology. In accordance with this effect, airflow velocity increases at the site of stricture in the airway. As airway velocity increases, pressure on the lateral wall decreases. If the transmural closing pressure is reached, the airway collapses. The Bernoulli effect is exaggerated in areas where the airway is most compliant. Loads on the pharyngeal walls increase adherence and, hence, increase the likelihood of collapse.
This effect helps to partially explain why obese patients, and particularly those with fat deposition in the neck, are most likely to have OSA. Moreover, the cross-sectional area of the airway in patients with OSA is smaller than that of people without OSA; this difference is due to the volume of the soft tissue, including the tongue, lateral pharyngeal walls, soft palate, and parapharyngeal fat pads. In one study, the increased volume of these areas was independent of sex, age, ethnicity, craniofacial size, and fat deposition surrounding the UA. 
Given these principles, it is understandable why the likelihood of OSA is increased among obese patients, why weight loss decreases the risk of OSA, and why physical examination helps in predicting the presence of OSA. However, the clinical situation is complex because of the interplay of known static and dynamic factors and because of unknown factors.
Data do not explain why sex, age, and ethnicity are not evenly distributed across epidemiologic studies of OSA patients. (See Epidemiology.) Furthermore, data or physical findings are not helpful for determining with precision who will or will not have OSA and who can or who cannot be cured with UA surgery.
OSA often occurs in clusters. An oxygen desaturation occurs with each apnea. The end of the apnea sequence typically ends with a brief (>3 sec) EEG arousal. In patients with severe OSA, the cluster of apneas occurs throughout sleep. The desaturation from the first apnea event is typically associated with a higher desaturation percentage change than subsequent apneas in the series.
An underlying mechanism for how clusters of apneas occur and the rate of oxygen desaturation has been recently studied.  The researchers paralyzed lambs and withdrew mechanical ventilation to produce apnea and target oxygen saturation. Once the target was reached and the number of recurrent apneas was met, they stimulated respiration through the ventilator so that oxygen saturation was more than 85%.
The study found that oxygen desaturation was not significantly correlated with resting oxygen saturation, independent of mixed-venous oxygen saturation, using forward stepwise regression modeling. It predicted increased desaturation rates solely based on the size of oxygen reuptake.  This occurs when mixed-venous blood with depleted oxygen saturation arrives at the lung in time with the apnea phase.
The rapid change in oxygen desaturation occurred after the second apnea in a series of 10 produced; apneas that followed the second apnea did not have accelerated changes when compared with the second apnea. Isolated apneas did not show rapid changes in oxygen saturation.
The clinical implications of these findings suggest that the reason why continuous positive airway pressure (CPAP) and supplemental oxygen may work to ameliorate rapid desaturation is related to the extent that apneas can remain isolated. This results in a longer ventilatory phase to allow venous reoxygenation.
It should be kept in mind that the events studied were not obstructive events but were apneas associated with hypoxemia. They were not terminated by EEG arousals in a natural way to end an apnea sequence and were not produced in humans. Therefore, this study’s clinical application is associated with several caveats.
An excellent review article by Gozal and Kheirandish-Gozal provides a model that attempts to integrate how oxidative stress and inflammatory processes link OSA and cardiovascular disease. 
Genetic studies have revealed that the gene that encodes for oxidative stress uniquely contributes toward OSA.  This suggests that the development of OSA may be related to inflammation and is not necessarily related to a trigger for oxidative stress, as was previously thought. The gene may play a pivotal role by operating in a positive feedback loop, causing the OSA to begin with and then triggering an inflammatory response that further narrows the UA, exacerbating the OSA.
The etiology of OSA involves both structural and nonstructural factors, including genetic factors.
Structural factors related to craniofacial bony anatomy that predispose patients with OSA to pharyngeal collapse during sleep include the following:
Innate anatomic variations (facial elongation, posterior facial compression)
Retrognathia and micrognathia
Brachycephalic head form – Associated with an increased AHI in whites but not in African Americans. 
Inferior displacement of the hyoid
Adenotonsillar hypertrophy, particularly in children and young adults
High, arched palate (particularly in women)
Structural factors related to nasal obstruction that predispose patients with OSA to pharyngeal collapse during sleep include polyps, septal deviation, tumors, trauma, and stenosis. Structural factors related to retropalatal obstruction include (1) an elongated, posteriorly placed palate and uvula and (2) tonsil and adenoid hypertrophy (particularly in children). Structural factors related to retroglossal obstruction include macroglossia and tumor.
Studies confirm that craniofacial abnormalities are important in the pathogenesis of OSA, particularly in nonobese patients and children. Moreover, given that different racial groups are inclined to develop OSA at varying degrees of obesity, clinicians should particularly consider the possibility of this disorder in the presence of clinically detectable craniofacial abnormalities. [28, 29]
Previous studies of craniofacial risk factors for OSA have been based predominantly on cephalometry. However, differences in head form (measured by the cranial index) and facial form (measured by the facial index) are considered by anthropologists to provide a basis for structural variation in craniofacial anatomy.
The association of head and facial form with the AHI was assessed in 364 whites and 165 African Americans. Cranial and facial dimensions were measured using anthropometric calipers, and other data collected included the body mass index (BMI), neck circumference, and the AHI.
Cranial index and facial index in whites with OSA (AHI ≥15) differ from those in whites without OSA (AHI < 5). The cranial index was increased and the facial index decreased in subjects with OSA. Cranial and facial indices did not differ in African American subjects based on OSA diagnosis. In whites with OSA, the cranial index was again greater and the facial index was again smaller than in African Americans. The researchers suggested that the cranial index may be useful in phenotyping and identifying population subsets with OSA. 
Nonstructural risk factors for OSA include the following:
Central fat distribution
Habitual snoring with daytime somnolence
Supine sleep position
Rapid eye movement (REM) sleep
Familial factors also play a role (see below).  Families with a high incidence of OSA are reported. Relatives of patients with SDB have a 2- to 4-fold increased risk of SDB compared with control subjects.
Other conditions associated with the development of OSA are as follows:
Hypothyroidism is associated with macroglossia and increased soft tissue mass in the pharyngeal region and thus with an increased risk of SDB. Hypothyroidism is also associated with myopathy that may contribute to UA dysfunction. Although it has been linked with the development of OSA, evidence indicates that its prevalence is no higher in patients with OSA than in the general population. Accordingly, patients with OSA should not be routinely screened for hypothyroidism, except possibly elderly women.
Neurologic syndromes associated with OSA include postpolio syndrome, muscular dystrophies, and autonomic failure syndromes such as Shy-Drager syndrome.
The relationship of OSA to cerebrovascular disease is still being determined. Growing evidence indicates that the prevalence of OSA is increased in patients who have had a stroke. However, whether OSA is a risk factor for stroke or stroke is a risk factor for developing OSA remains unclear.
Like hypothyroidism, acromegaly is associated with macroglossia and increased soft tissue mass in the pharyngeal region and thus with an increased risk of SDB.
Environmental exposures include smoke, environmental irritants or allergens, and alcohol and hypnotic-sedative medications.
A study examined 52 candidate genes most likely to influence OSA.  The study sample included 792 African Americans and 694 European Americans, all older than 18 years. An AHI of 15 or higher was used to define OSA as a clinical entity; the AHI was statistically used as both a continuous and a dichotomous trait. In the African American subjects, 1,080 single nucleotide polymorphisms (SNPs) were genotypes; in the European Americans, 505 SNPs were genotypes. Statistical analysis controlled for adjusted for age, age-squared, and sex, with and without BMI.
The study found the following variants in European Americans: C-reactive protein (CRP) and glial cell line-derived neurotrophic factor (GDNF) were associated with the AHI as both a longitudinal and a dichotomous trait. CRP findings increased the odds ratio for the risk of OSA between 1.45 and 2.87; GDNF increased the odds ratio between 1.53 and 3.89-3.92 for the GDNF gene that looked at risk allele G and GDNF risk allele A, respectively.
The study found the following variant in African Americans with OSA: r9s526240 within serotonin receptor 2a. Risk allele A increased the odds ratio for risk of obstructive sleep apnea from 1.45-2.91 using the reported 95% confidence interval.
CRP appears to mediate inflammation; it is thought to be a marker of inflammation. Such inflammation may increase OSA by increasing mucosal edema and reducing airway caliber.
GDNF influences ventilatory control. It appears to sense oxygen and carbon dioxide at sleep onset transitions, hence playing a role in CSA. GDNF influences the growth of sensory afferent neurons of the carotid body, influencing responses to hypoxia. Its role extends to influencing the growth of neural pathways that are important for normal respiration, specifically at the A5 nucleus of the ventrolateral pons, a critical area that regulates respiratory pattern generation.
The role of 5HT2A includes effects on sleep-wake cycles, importantly influencing rapid eye movement (REM) sleep stage percentage. Medications such as selective serotonin reuptake inhibitors (SSRIs) that occupy 5HT2A receptors reduce or eliminate REM sleep percent time. Other mentioned roles include regulation of upper airway dilator muscle through an excitatory influence on hypoglossal motor output. 5HT2a is involved in appetite regulation, thus playing a role in obesity, a well-known risk factor for obstructive sleep apnea.
The study used rather strict criteria to identify other candidate genes, and less stringent criteria identified other possible candidate genes that may influence the risk of OSA.
SDB is common in the United States. The National Commission on Sleep Disorders Research estimated that minimal SDB (RDI >5) affects 7-18 million people in the United States and that relatively severe cases (RDI >15) affect 1.8-4 million people. The prevalence increases with age. SDB remains undiagnosed in approximately 92% of affected women and 80% of affected men.
OSA is increasingly prevalent, in both adults and children, in modern society. The estimated prevalence has been 2% for women and 4% for men. [31, 32] Similar data have been found in an epidemiologic study from Pennsylvania. [10, 33] More recent research indicates a prevalence of 4% for women and 9% for men. Data from the Wisconsin Cohort Study indicate that the prevalence of OSA in people aged 30-60 years is 9-24% for men and 4-9% for women.
The prevalence in children is less certain, but the author’s sleep center is seeing increasing numbers of adolescent patients, who are often obese and present similarly to many of their adult counterparts, with the important exception that they may be sleepy and/or hyperactive. A 2007 study has suggested that approximately 6% of adolescents have weekly SDB. 
The prevalence of OSA in non-American populations has only been studied in men and has been found to be as low as 0.3% (England) and as high as 20-25% (Israel and Australia). The prevalence of OSA in Australian men is estimated to be 3%.
Aging is an important consideration of risk for OSA. OSA prevalence increases 2-3 times in older persons (>65 y) compared with individuals aged 30-64 years, [35, 36] with an estimated rate as high as 65% in a community sample of people older than 65 years. 
After age 65 years, no further relative disparity is noted in the incidence of OSA. One explanation for this plateau is the relative increase in mortality in persons older than 65 years; however, data to support this contention, as attractive as it appears, are insufficient. Scant data are available to help clinicians determine if clinical management should differ between the age cohorts.
The male-to-female ratio in community-based studies is 2-3:1. [31, 38] Androgenic patterns of body fat distribution (deposition in the trunk, including the neck area) predispose men to OSA. In general, sex hormones may affect neurologic control of UA-dilating muscles and ventilation.
In population studies that have examined the incidence of OSA, women were not only less likely than men to have OSA but also less likely to be diagnosed early in the disease process. Survival rates are lower for women than for men, after an OSA diagnosis has been established by PSG, presumably due to the delayed OSA diagnosis.
Three large epidemiologic studies have demonstrated that the prevalence of OSA in women appears to increase after menopause. [39, 40, 41] In these studies, women on hormone replacement therapy (HRT) had a prevalence similar to that of premenopausal women. Postmenopausal women are 3 times more likely to have moderate-to-severe OSA compared with premenopausal women. Women who are on HRT are half as likely to have OSA compared with postmenopausal women who are not on HRT. 
Premenopausal women with OSAHS tend to be more obese than men with the same severity of disease. Thin women with symptoms of OSAHS appear to have an increased frequency of craniofacial abnormalities.
Evidence indicates that women underreport the symptoms of loud snoring and witnessed apneas, leading to underreferral to sleep centers. This may explain the marked male predominance (male-to-female ratio of approximately 8:1) in sleep center–based studies. Additionally, women have lower AHIs than men, even after correcting for other demographic factors such as BMI and neck circumference. [43, 44, 45]
African American individuals appear to be more predisposed to SDB than white persons. This increased predisposition varies according to age. The odds ratio is greater than 3 in children younger than 13 years and is 1.88 in persons younger than 25 years. In elderly African Americans, the risk is increased 2-fold. Examination of craniofacial morphology found that brachycephaly is associated with an increased AHI in whites but not in African Americans. 
Chinese patients with OSA have a more crowded upper airway and relative retrognathia compared with their white counterparts, with statistical controls for BMI and neck circumference.  Asians are known to have a shorter cranial base and a more acute cranial base flexure, increasing OSA risk, with BMI and neck circumference being roughly equal. Therefore, interestingly, obesity plays a more prominent role in OSA predisposition in whites than in Chinese persons. This may serve to underscore the role that craniofacial factors have in Chinese patients.
Other populations that may be at increased risk include Mexican Americans and Pacific Islanders.
The short-term prognosis, in relation to symptoms such as daytime sleepiness and snoring, ranges from good to excellent with regular use of CPAP. Several studies, including placebo-controlled studies, have shown significant improvement in measures of cognitive function and general health status (eg, as measured by the Medical Outcome Study Short-Form 36 health survey) after 4-8 weeks of treatment with CPAP. However, studies have not been performed in a large population or for more than a 4- to 8-week treatment period.
The long-term prognosis is unknown because no randomized treatment studies investigating the effect of CPAP on preventing the development of cardiovascular sequelae have been conducted.
The effect of OSA on mortality has been investigated using observational cohort studies. Marin et al found in a Spanish cohort that severe untreated OSA (AHI >30) is associated with an increased risk of cardiovascular mortality, defined by fatal myocardial infarction (MI) or stroke.  Patients with mild OSA or those undergoing treatment with CPAP did not have a significantly increased odds ratio compared with a group of subjects without OSA. 
In this study, the authors also found that untreated severe OSA is a significant risk factor for the development of cardiovascular morbidity, which included nonfatal MI and stroke.
Two 2008 population-based studies, one from the United States  and one from Australia,  also showed increased all-cause mortality in subjects with moderate-to severe OSA. The adjusted hazard ratios in both studies ranged from 3-6.24 for subjects with moderate-to-severe disease compared with no disease.
In the Sleep Heart Health Study,  6441 men and women were followed for a mean of 8.2 years. Increased mortality was observed in patients with OSA, but the effect was primarily observed in men younger than 70 years. Women and men older than 70 years did not have increased mortality. In addition, the increased mortality was seen primarily in patients with the most oxygen desaturation during their sleep.
A 2012 study examined the association between OSA and mortality. Using portable sleep studies with more than 77,000 patients, the authors found that OSA was associated with all-cause mortality in patients younger than 50 years of age. While this is a general conclusion from the study, other variables played a substantial role in mediating this relationship. These data are consistent with earlier data showing that the negative impact of OSA on health is more profound in younger patients. 
Campos-Rodriguez et al reported that severe OSA is associated with cardiovascular death in women, and adequate CPAP treatment may reduce this risk.  A study in the elderly also suggests that severe OSA not treated with CPAP is associated with an increased risk of cardiovascular death. 
Several other studies indicate that CPAP mitigates the increased mortality observed in OSA. In addition to the article from Spain discussed above, a 2005 article  suggests that mortality is associated with compliance with CPAP. In a historical cohort of 871 patients, patients who used CPAP more than 6 hours per night had an increased survival rate (96.4%) at 5 years compared with those who used CPAP 1-6 hours per night (91.3%) and less than 1 hour per night (85.5%). Use for more than 6 hours per night was associated with a significantly decreased odds ratio of 0.1.
Patients with a history of ischemic stroke and sleep apnea who regularly used their CPAP device had a decreased mortality compared with those who did not use their CPAP device. 
A 2005 study found that OSA was associated with an increased risk of sudden death between the hours of midnight and 6 AM, as compared with the general population (in whom sudden death is more common between 6 AM and noon). 
Evidence indicates that OSA is not an independent risk factor for the development of pulmonary hypertension in the absence of other lung disease, as evidenced by the presence of daytime hypoxemia, hypercapnia, or obstructive airway disease. 
A study of 150 newly diagnosed patients with OSA by Baguet determined that left ventricular diastolic dysfunction is common in these patients and is related to the severity of oxygen desaturation. 
All of the above evidence strongly suggests that OSA is an independent risk factor for the development of cardiovascular disease and death. However, at this time, no definitive randomized studies have investigated the effect of CPAP in preventing the potential cardiovascular risks.
Many studies have identified a relationship between OSA and motor vehicle accidents. Patients with OSA have been reported to be 2-7 times as likely as control individuals to have a motor vehicle crash; the overall estimated risk was 2.5 in a meta-analysis of 6 studies.  Many studies indicate that motor vehicle accidents are more common in patients with severe OSA (generally, AHI >30), [59, 60] but this is not a universal finding. 
Methods for predicting if an individual patient will have an automobile accident are not yet sufficiently reliable. Using increasingly refined and realistic driving simulators, Ghosh et al could predict those who failed a driving simulation test compared to those who passed the test. The simulation is a step forward in prediction, but simulation has not yet reached levels that would allow a clinician to determine if an OSA patient is safe to drive a vehicle or not. Though the more severely impaired OSA patients were selected for the study, many of them were able to finish the 50-minute driving simulator without incident. The authors continue to work to refine the simulator. It would be an advance to find a test that is sufficiently reliable for use in the clinical setting. 
A study from Australia found that truck drivers with Epworth Sleepiness Scale (ESS) scores higher than 18 had an odds ratio of 2.67 for multiple accidents. 
An Internet-linked survey of 35,217 respondents found that subjects who reported at least one near-miss sleepy accident were 1.13 times as likely to have had one actual accident compared with subjects not reporting a near-miss accident.  The odds ratio increased to 1.87 for those reporting 4 or more near-miss sleepy accidents. This study indicates that asking patients about near-miss sleepy accidents may be predictive of future accident risk.
Predicting accident risk in patients with OSA is difficult because many individuals with OSA do not accurately perceive their level of drowsiness. No evidence indicates that sleep latency derived from either the multiple sleep latency test (MSLT; a measure of sleep propensity) or the maintenance of wakefulness test (MWT; a measure of wake tendency) are predictive of accident risk.
A large body of work has been compiled on the influence of OSA on driving-simulator performance, with most studies indicating poor performance, similar to that seen with alcohol impairment while driving [65, 66] (though performance may return to normal after treatment). However, whether driving-simulator performance is an accurate predictor of real-world driving is unclear,  and no evidence indicates that simulator performance can be used to predict accident risk in OSA patients. 
Evidence indicates that CPAP improves driving performance. At least 2 studies have shown improvement on a driving simulator after CPAP use. [69, 70] Specifically, in one study, the number of off-road events decreased from 17.8 to 9 after 1 month of effective CPAP therapy, but no change was noted after a month of ineffective pressure set at 1 cm water.
In addition, 2 studies have looked at the effect of CPAP on actual motor vehicle accident rates. George derived crash rates from Department of Motor Vehicle data for 210 patients with OSA over a 3-year period before and after CPAP therapy; the crash rate was 0.18 while untreated, but fell to 0.06 with treatment.  Findley et al reported no further crashes in a group of 36 patients with OSA regularly using CPAP therapy.  Thus, evidence suggests that effective treatment of OSA should decrease accident rates.
Despite the elevated risk of crashing, most patients with OSA have not had a crash; therefore, determining which OSA patients are likely to have an accident, which patients should have driving restrictions, and how much benefit would accrue from these restrictions is not clear. 
No recent evidence-based guidelines are available regarding driving for the average patient with OSA. The most recent statement on this topic is from 1994. 
One approach to this problem outlined in the 1994 statement is the concept of shared responsibilities. Educating the patient about the risks of driving while sleepy or inattentive is the physician’s responsibility. One suggestion is that the patient acknowledges this education by signing a statement to that effect. After receiving proper education, the patient’s responsibilities are to avoid driving while sleepy and, preferably, to refrain from driving until starting treatment for OSA.
Physicians should be referred to their individual state or country motor vehicle departments for local guidelines.
All patients should receive education about sleep and proper sleep hygiene, OSA, and the risks of driving while sleepy. They also should receive education regarding the role of nasal CPAP and the importance of daily use, as well as training in the use of CPAP, from a physician, trained technician, or nurse for at least the first month of therapy. This training promotes long-term adherence with treatment.
For more information, see the Ear, Nose, and Throat Center; Mental Health and Behavior Center; and Sleep Disorders Center, as well as Snoring, Fatigue, Insomnia, Sleep Disorders in Women, and Sleep Disorders and Aging.
Guilleminault C, Tilkian A, Dement WC. The sleep apnea syndromes. Annu Rev Med. 1976. 27:465-84. [Medline].
Iber C, Ancoli-Israel S, Chesson AL, Quan SF. The AASM Manual for the Scoring of Sleep and Associated Events. Westchester, IL: American Academy of Sleep Medicine; 2007.
Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep. 1997 Sep. 20(9):705-6. [Medline].
American Academy of Sleep Medicine. International Classification of Sleep Disorders. Diagnostic and Coding Manual. Second Edition. Westchester, Ill: American Academy of Sleep Medicine; 2005.
Downey R 3rd, Perkin RM, MacQuarrie J. Upper airway resistance syndrome: sick, symptomatic but underrecognized. Sleep. 1993 Oct. 16(7):620-3. [Medline].
Lugaresi E, Mondini S, Zucconi M, Montagna P, Cirignotta F. Staging of heavy snorers’ disease. A proposal. Bull Eur Physiopathol Respir. 1983 Nov-Dec. 19(6):590-4. [Medline].
Hoffstein V. Snoring. Chest. 1996 Jan. 109(1):201-22. [Medline].
Bonnet MH. Effect of sleep disruption on sleep, performance, and mood. Sleep. 1985. 8(1):11-9. [Medline].
Schwab RJ, Pasirstein M, Pierson R, Mackley A, Hachadoorian R, Arens R, et al. Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imaging. Am J Respir Crit Care Med. 2003 Sep 1. 168(5):522-30. [Medline].
White DP. Sleep apnea. Proc Am Thorac Soc. 2006. 3(1):124-8. [Medline].
White DP. The pathogenesis of obstructive sleep apnea: advances in the past 100 years. Am J Respir Cell Mol Biol. 2006 Jan. 34(1):1-6. [Medline].
McGinley BM, Schwartz AR, Schneider H, Kirkness JP, Smith PL, Patil SP. Upper airway neuromuscular compensation during sleep is defective in obstructive sleep apnea. J Appl Physiol. 2008 Jul. 105(1):197-205. [Medline]. [Full Text].
Patil SP, Schneider H, Marx JJ, Gladmon E, Schwartz AR, Smith PL. Neuromechanical control of upper airway patency during sleep. J Appl Physiol. 2007 Feb. 102(2):547-56. [Medline].
Xie A, Skatrud JB, Puleo DS, Rahko PS, Dempsey JA. Apnea-hypopnea threshold for CO2 in patients with congestive heart failure. Am J Respir Crit Care Med. 2002 May 1. 165(9):1245-50. [Medline].
Leung RS, Bradley TD. Sleep apnea and cardiovascular disease. Am J Respir Crit Care Med. 2001 Dec 15. 164(12):2147-65. [Medline].
Xie A, Rutherford R, Rankin F, Wong B, Bradley TD. Hypocapnia and increased ventilatory responsiveness in patients with idiopathic central sleep apnea. Am J Respir Crit Care Med. 1995 Dec. 152(6 Pt 1):1950-5. [Medline].
Badr MS, Toiber F, Skatrud JB, Dempsey J. Pharyngeal narrowing/occlusion during central sleep apnea. J Appl Physiol. 1995 May. 78(5):1806-15. [Medline].
Onal E, Burrows DL, Hart RH, Lopata M. Induction of periodic breathing during sleep causes upper airway obstruction in humans. J Appl Physiol. 1986 Oct. 61(4):1438-43. [Medline].
Hudgel DW, Chapman KR, Faulks C, Hendricks C. Changes in inspiratory muscle electrical activity and upper airway resistance during periodic breathing induced by hypoxia during sleep. Am Rev Respir Dis. 1987 Apr. 135(4):899-906. [Medline].
Warner G, Skatrud JB, Dempsey JA. Effect of hypoxia-induced periodic breathing on upper airway obstruction during sleep. J Appl Physiol. 1987 Jun. 62(6):2201-11. [Medline].
Badr MS, Kawak A, Skatrud JB, Morrell MJ, Zahn BR, Babcock MA. Effect of induced hypocapnic hypopnea on upper airway patency in humans during NREM sleep. Respir Physiol. 1997 Oct. 110(1):33-45. [Medline].
Zhou XS, Shahabuddin S, Zahn BR, Babcock MA, Badr MS. Effect of gender on the development of hypocapnic apnea/hypopnea during NREM sleep. J Appl Physiol. 2000 Jul. 89(1):192-9. [Medline].
Sands SA, Edwards BA, Kelly VJ, Skuza EM, Davidson MR, Wilkinson MH, et al. Mechanism underlying accelerated arterial oxygen desaturation during recurrent apnea. Am J Respir Crit Care Med. 2010 Oct 1. 182(7):961-9. [Medline].
Gozal D, Kheirandish-Gozal L. Cardiovascular morbidity in obstructive sleep apnea: oxidative stress, inflammation, and much more. Am J Respir Crit Care Med. 2008 Feb 15. 177(4):369-75. [Medline]. [Full Text].
Larkin EK, Patel SR, Goodloe RJ, Li Y, Zhu X, Gray-McGuire C, et al. A candidate gene study of obstructive sleep apnea in European Americans and African Americans. Am J Respir Crit Care Med. 2010 Oct 1. 182(7):947-53. [Medline]. [Full Text].
Cakirer B, Hans MG, Graham G, Aylor J, Tishler PV, Redline S. The relationship between craniofacial morphology and obstructive sleep apnea in whites and in African-Americans. Am J Respir Crit Care Med. 2001 Mar. 163(4):947-50. [Medline].
Rowley JA, Aboussouan LS, Badr MS. The use of clinical prediction formulas in the evaluation of obstructive sleep apnea. Sleep. 2000 Nov 1. 23(7):929-38. [Medline].
Redline S, Tishler PV, Tosteson TD, Williamson J, Kump K, Browner I, et al. The familial aggregation of obstructive sleep apnea. Am J Respir Crit Care Med. 1995 Mar. 151(3 Pt 1):682-7. [Medline].
Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993 Apr 29. 328(17):1230-5. [Medline].
Centers for Medicare and Medicaid Services. Decision Memo for Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea (OSA) (CAG-00093R2). [Full Text].
Goetting, C , Downey III R. Sick, symptomatic and undiagnosed. 2010.
Johnson EO, Roth T. An epidemiologic study of sleep-disordered breathing symptoms among adolescents. Sleep. 2006 Sep 1. 29(9):1135-42. [Medline].
Bixler EO, Vgontzas AN, Ten Have T, Tyson K, Kales A. Effects of age on sleep apnea in men: I. Prevalence and severity. Am J Respir Crit Care Med. 1998 Jan. 157(1):144-8. [Medline].
Young T, Shahar E, Nieto FJ, Redline S, Newman AB, Gottlieb DJ, et al. Predictors of sleep-disordered breathing in community-dwelling adults: the Sleep Heart Health Study. Arch Intern Med. 2002 Apr 22. 162(8):893-900. [Medline].
Redline S, Kump K, Tishler PV, Browner I, Ferrette V. Gender differences in sleep disordered breathing in a community-based sample. Am J Respir Crit Care Med. 1994 Mar. 149(3 Pt 1):722-6. [Medline].
Hla KM, Young TB, Bidwell T, Palta M, Skatrud JB, Dempsey J. Sleep apnea and hypertension. A population-based study. Ann Intern Med. 1994 Mar 1. 120(5):382-8. [Medline].
Shahar E, Redline S, Young T, Boland LL, Baldwin CM, Nieto FJ, et al. Hormone replacement therapy and sleep-disordered breathing. Am J Respir Crit Care Med. 2003 May 1. 167(9):1186-92. [Medline].
Young T, Finn L, Austin D, Peterson A. Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med. 2003 May 1. 167(9):1181-5. [Medline].
Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA. 2004 Apr 28. 291(16):2013-6. [Medline].
O’Connor C, Thornley KS, Hanly PJ. Gender differences in the polysomnographic features of obstructive sleep apnea. Am J Respir Crit Care Med. 2000 May. 161(5):1465-72. [Medline].
Ware JC, McBrayer RH, Scott JA. Influence of sex and age on duration and frequency of sleep apnea events. Sleep. 2000 Mar 15. 23(2):165-70. [Medline].
Dancey DR, Hanly PJ, Soong C, Lee B, Shepard J Jr, Hoffstein V. Gender differences in sleep apnea: the role of neck circumference. Chest. 2003 May. 123(5):1544-50. [Medline].
Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005 Mar 19-25. 365(9464):1046-53. [Medline].
Young T, Finn L, Peppard PE, Szklo-Coxe M, Austin D, Nieto FJ, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep. 2008 Aug 1. 31(8):1071-8. [Medline]. [Full Text].
Marshall NS, Wong KK, Liu PY, Cullen SR, Knuiman MW, Grunstein RR. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep. 2008 Aug 1. 31(8):1079-85. [Medline]. [Full Text].
Punjabi NM, Caffo BS, Goodwin JL, Gottlieb DJ, Newman AB, O’Connor GT, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med. 2009 Aug. 6(8):e1000132. [Medline]. [Full Text].
Rich J, Raviv A, Raviv N, Brietzke SE. All-Cause Mortality and Obstructive Sleep Apnea Severity Revisited. Otolaryngol Head Neck Surg. 2012 Jun 11. [Medline].
Campos-Rodriguez F, Martinez-Garcia MA, de la Cruz-Moron I, Almeida-Gonzalez C, Catalan-Serra P, Montserrat JM. Cardiovascular mortality in women with obstructive sleep apnea with or without continuous positive airway pressure treatment: a cohort study. Ann Intern Med. 2012 Jan 17. 156(2):115-22. [Medline].
Martinez-Garcia MA, Campos-Rodriguez F, Catalan-Serra P, Soler-Cataluna JJ, Almeida-Gonzalez C, De la Cruz Moron I, et al. Cardiovascular mortality in obstructive sleep apnea in the elderly: role of long-term continuous positive airway pressure treatment: a prospective observational study. Am J Respir Crit Care Med. 2012 Nov 1. 186(9):909-16. [Medline].
Campos-Rodriguez F, Pena-Grinan N, Reyes-Nunez N, De la Cruz-Moron I, Perez-Ronchel J, De la Vega-Gallardo F, et al. Mortality in obstructive sleep apnea-hypopnea patients treated with positive airway pressure. Chest. 2005 Aug. 128(2):624-33. [Medline].
Martinez-Garcia MA, Soler-Cataluna JJ, Ejarque-Martinez L, Soriano Y, Roman-Sanchez P, Illa FB, et al. Continuous positive airway pressure treatment reduces mortality in patients with ischemic stroke and obstructive sleep apnea: a 5-year follow-up study. Am J Respir Crit Care Med. 2009 Jul 1. 180(1):36-41. [Medline].
Gami AS, Howard DE, Olson EJ, Somers VK. Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med. 2005 Mar 24. 352(12):1206-14. [Medline].
Chaouat A, Weitzenblum E, Krieger J, Oswald M, Kessler R. Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients. Chest. 1996 Feb. 109(2):380-6. [Medline].
Baguet JP, Barone-Rochette G, Levy P, Vautrin E, Pierre H, Ormezzano O, et al. Left ventricular diastolic dysfunction is linked to severity of obstructive sleep apnoea. Eur Respir J. 2010 Dec. 36(6):1323-9. [Medline].
Sassani A, Findley LJ, Kryger M, Goldlust E, George C, Davidson TM. Reducing motor-vehicle collisions, costs, and fatalities by treating obstructive sleep apnea syndrome. Sleep. 2004 May 1. 27(3):453-8. [Medline].
Horstmann S, Hess CW, Bassetti C, Gugger M, Mathis J. Sleepiness-related accidents in sleep apnea patients. Sleep. 2000 May 1. 23(3):383-9. [Medline].
George CF, Smiley A. Sleep apnea & automobile crashes. Sleep. 1999 Sep 15. 22(6):790-5. [Medline].
Barbe, Pericas J, Munoz A, Findley L, Anto JM, Agustí AG. Automobile accidents in patients with sleep apnea syndrome. An epidemiological and mechanistic study. Am J Respir Crit Care Med. 1998 Jul. 158(1):18-22. [Medline].
Ghosh D, Jamson SL, Baxter PD, Elliott MW. Continuous measures of driving performance on an advanced office-based driving simulator can be used to predict simulator task failure in patients with obstructive sleep apnoea syndrome. Thorax. 2012 May 5. [Medline].
Howard ME, Desai AV, Grunstein RR, Hukins C, Armstrong JG, Joffe D, et al. Sleepiness, sleep-disordered breathing, and accident risk factors in commercial vehicle drivers. Am J Respir Crit Care Med. 2004 Nov 1. 170(9):1014-21. [Medline].
Powell NB, Schechtman KB, Riley RW, Guilleminault C, Chiang RP, Weaver EM. Sleepy driver near-misses may predict accident risks. Sleep. 2007 Mar 1. 30(3):331-42. [Medline].
Risser MR, Ware JC, Freeman FG. Driving simulation with EEG monitoring in normal and obstructive sleep apnea patients. Sleep. 2000 May 1. 23(3):393-8. [Medline].
George CF, Boudreau AC, Smiley A. Comparison of simulated driving performance in narcolepsy and sleep apnea patients. Sleep. 1996 Nov. 19(9):711-7. [Medline].
Philip P, Sagaspe P, Taillard J, Valtat C, Moore N, Akerstedt T, et al. Fatigue, sleepiness, and performance in simulated versus real driving conditions. Sleep. 2005 Dec 1. 28(12):1511-6. [Medline].
Turkington PM, Sircar M, Allgar V, Elliott MW. Relationship between obstructive sleep apnoea, driving simulator performance, and risk of road traffic accidents. Thorax. 2001 Oct. 56(10):800-5. [Medline]. [Full Text].
Hack M, Davies RJ, Mullins R, Choi SJ, Ramdassingh-Dow S, Jenkinson C, et al. Randomised prospective parallel trial of therapeutic versus subtherapeutic nasal continuous positive airway pressure on simulated steering performance in patients with obstructive sleep apnoea. Thorax. 2000 Mar. 55(3):224-31. [Medline]. [Full Text].
Turkington PM, Sircar M, Saralaya D, Elliott MW. Time course of changes in driving simulator performance with and without treatment in patients with sleep apnoea hypopnoea syndrome. Thorax. 2004 Jan. 59(1):56-9. [Medline]. [Full Text].
Findley L, Smith C, Hooper J, Dineen M, Suratt PM. Treatment with nasal CPAP decreases automobile accidents in patients with sleep apnea. Am J Respir Crit Care Med. 2000 Mar. 161(3 Pt 1):857-9. [Medline].
Pack AI, Pien GW. How much do crashes related to obstructive sleep apnea cost?. Sleep. 2004 May 1. 27(3):369-70. [Medline].
American Thoracic Society. Sleep apnea, sleepiness, and driving risk. American Thoracic Society. Am J Respir Crit Care Med. 1994 Nov. 150(5 Pt 1):1463-73. [Medline].
Punjabi NM, Bandeen-Roche K, Young T. Predictors of objective sleep tendency in the general population. Sleep. 2003 Sep. 26(6):678-83. [Medline].
Benbadis SR, Mascha E, Perry MC, Wolgamuth BR, Smolley LA, Dinner DS. Association between the Epworth sleepiness scale and the multiple sleep latency test in a clinical population. Ann Intern Med. 1999 Feb 16. 130(4 Pt 1):289-92. [Medline].
Chervin RD, Aldrich MS. The Epworth Sleepiness Scale may not reflect objective measures of sleepiness or sleep apnea. Neurology. 1999 Jan 1. 52(1):125-31. [Medline].
Punjabi NM, O’hearn DJ, Neubauer DN, Nieto FJ, Schwartz AR, Smith PL, et al. Modeling hypersomnolence in sleep-disordered breathing. A novel approach using survival analysis. Am J Respir Crit Care Med. 1999 Jun. 159(6):1703-9. [Medline].
Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep. 2005 Apr 1. 28(4):464-71. [Medline].
Chervin RD. Sleepiness, fatigue, tiredness, and lack of energy in obstructive sleep apnea. Chest. 2000 Aug. 118(2):372-9. [Medline].
Castronovo V, Canessa N, Strambi LF, Aloia MS, Consonni M, Marelli S, et al. Brain activation changes before and after PAP treatment in obstructive sleep apnea. Sleep. 2009 Sep 1. 32(9):1161-72. [Medline]. [Full Text].
Freedman DS, Khan LK, Serdula MK, Galuska DA, Dietz WH. Trends and correlates of class 3 obesity in the United States from 1990 through 2000. JAMA. 2002 Oct 9. 288(14):1758-61. [Medline].
Nuckton TJ, Glidden DV, Browner WS, Claman DM. Physical examination: Mallampati score as an independent predictor of obstructive sleep apnea. Sleep. 2006 Jul 1. 29(7):903-8. [Medline].
Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology. 2008 May. 108(5):812-21. [Medline].
Chung F, Subramanyam R, Liao P, Sasaki E, Shapiro C, Sun Y. High STOP-Bang score indicates a high probability of obstructive sleep apnoea. Br J Anaesth. 2012 May. 108(5):768-75. [Medline]. [Full Text].
Ramachandran SK, Kheterpal S, Consens F, Shanks A, Doherty TM, Morris M, et al. Derivation and validation of a simple perioperative sleep apnea prediction score. Anesth Analg. 2010 Apr 1. 110(4):1007-15. [Medline].
Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, et al. Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation. 2008 Sep 2. 118(10):1080-111. [Medline].
Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000 Apr 12. 283(14):1829-36. [Medline].
Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000 May 11. 342(19):1378-84. [Medline].
O’Connor GT, Caffo B, Newman AB, Quan SF, Rapoport DM, Redline S, et al. Prospective study of sleep-disordered breathing and hypertension: the Sleep Heart Health Study. Am J Respir Crit Care Med. 2009 Jun 15. 179(12):1159-64. [Medline]. [Full Text].
Becker HF, Jerrentrup A, Ploch T, Grote L, Penzel T, Sullivan CE, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation. 2003 Jan 7. 107(1):68-73. [Medline].
Faccenda JF, Mackay TW, Boon NA, Douglas NJ. Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med. 2001 Feb. 163(2):344-8. [Medline].
Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson C, Stradling JR, et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet. 2002 Jan 19. 359(9302):204-10. [Medline].
Barbe F, Durán-Cantolla J, Capote F, de la Pena M, Chiner E, Masa JF, et al. Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med. 2010 Apr 1. 181(7):718-26. [Medline].
Pepin JL, Tamisier R, Barone-Rochette G, Launois SH, Levy P, Baguet JP. Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. Am J Respir Crit Care Med. 2010 Oct 1. 182(7):954-60. [Medline].
Drager LF, Bortolotto LA, Lorenzi MC, Figueiredo AC, Krieger EM, Lorenzi-Filho G. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med. 2005 Sep 1. 172(5):613-8. [Medline].
Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med. 2007 Oct 1. 176(7):706-12. [Medline].
Wang H, Parker JD, Newton GE, Floras JS, Mak S, Chiu KL, et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol. 2007 Apr 17. 49(15):1625-31. [Medline].
Kaneko Y, Floras JS, Usui K, Plante J, Tkacova R, Kubo T, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med. 2003 Mar 27. 348(13):1233-41. [Medline].
Javaheri S, Caref EB, Chen E, Tong KB, Abraham WT. Sleep apnea testing and outcomes in a large cohort of medicare beneficiaries with newly diagnosed heart failure. Am J Respir Crit Care Med. 2011 Feb 15. 183(4):539-46. [Medline].
Montemurro LT, Floras JS, Millar PJ, Kasai T, Gabriel JM, Spaak J, et al. Inverse Relationship of Subjective Daytime Sleepiness to Sympathetic Activity in Heart Failure Patients with Obstructive Sleep Apnea. Chest. 2012 Apr 26. [Medline].
Mehra R, Stone KL, Varosy PD, Hoffman AR, Marcus GM, Blackwell T, et al. Nocturnal Arrhythmias across a spectrum of obstructive and central sleep-disordered breathing in older men: outcomes of sleep disorders in older men (MrOS sleep) study. Arch Intern Med. 2009 Jun 22. 169(12):1147-55. [Medline]. [Full Text].
Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001 Jan. 163(1):19-25. [Medline].
Arzt M, Young T, Finn L, Skatrud JB, Bradley TD. Association of sleep-disordered breathing and the occurrence of stroke. Am J Respir Crit Care Med. 2005 Dec 1. 172(11):1447-51. [Medline]. [Full Text].
Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005 Nov 10. 353(19):2034-41. [Medline].
Munoz R, Duran-Cantolla J, Martinez-Vila E, Gallego J, Rubio R, Aizpuru F, et al. Severe sleep apnea and risk of ischemic stroke in the elderly. Stroke. 2006 Sep. 37(9):2317-21. [Medline].
Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med. 2002 Mar 1. 165(5):670-6. [Medline].
Punjabi NM, Sorkin JD, Katzel LI, Goldberg AP, Schwartz AR, Smith PL. Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med. 2002 Mar 1. 165(5):677-82. [Medline].
Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol. 2004 Sep 15. 160(6):521-30. [Medline].
Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med. 2002 Apr 1. 165(7):934-9. [Medline].
Lavie L, Vishnevsky A, Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep. 2004 Feb 1. 27(1):123-8. [Medline].
Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation. 2003 Mar 4. 107(8):1129-34. [Medline].
Larkin EK, Rosen CL, Kirchner HL, Storfer-Isser A, Emancipator JL, Johnson NL, et al. Variation of C-reactive protein levels in adolescents: association with sleep-disordered breathing and sleep duration. Circulation. 2005 Apr 19. 111(15):1978-84. [Medline].
Minoguchi K, Yokoe T, Tazaki T, Minoguchi H, Tanaka A, Oda N, et al. Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med. 2005 Sep 1. 172(5):625-30. [Medline].
Tazaki T, Minoguchi K, Yokoe T, Samson KT, Minoguchi H, Tanaka A, et al. Increased levels and activity of matrix metalloproteinase-9 in obstructive sleep apnea syndrome. Am J Respir Crit Care Med. 2004 Dec 15. 170(12):1354-9. [Medline].
Taheri S, Austin D, Lin L, Nieto FJ, Young T, Mignot E. Correlates of serum C-reactive protein (CRP)–no association with sleep duration or sleep disordered breathing. Sleep. 2007 Aug 1. 30(8):991-6. [Medline]. [Full Text].
Patt BT, Jarjoura D, Haddad DN, Sen CK, Roy S, Flavahan NA, et al. Endothelial dysfunction in the microcirculation of patients with obstructive sleep apnea. Am J Respir Crit Care Med. 2010 Dec 15. 182(12):1540-5. [Medline].
Ip MS, Lam B, Chan LY, Zheng L, Tsang KW, Fung PC, et al. Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care Med. 2000 Dec. 162(6):2166-71. [Medline].
Ip MS, Tse HF, Lam B, Tsang KW, Lam WK. Endothelial function in obstructive sleep apnea and response to treatment. Am J Respir Crit Care Med. 2004 Feb 1. 169(3):348-53. [Medline].
Imadojemu VA, Gleeson K, Quraishi SA, Kunselman AR, Sinoway LI, Leuenberger UA. Impaired vasodilator responses in obstructive sleep apnea are improved with continuous positive airway pressure therapy. Am J Respir Crit Care Med. 2002 Apr 1. 165(7):950-3. [Medline].
Nieto FJ, Herrington DM, Redline S, Benjamin EJ, Robbins JA. Sleep apnea and markers of vascular endothelial function in a large community sample of older adults. Am J Respir Crit Care Med. 2004 Feb 1. 169(3):354-60. [Medline].
Aronsohn RS, Whitmore H, Van Cauter E, Tasali E. Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. Am J Respir Crit Care Med. 2010 Mar 1. 181(5):507-13. [Medline]. [Full Text].
Pelletier-Fleury N, Rakotonanahary D, Fleury B. The age and other factors in the evaluation of compliance with nasal continuous positive airway pressure for obstructive sleep apnea syndrome. A Cox’s proportional hazard analysis. Sleep Med. 2001 May. 2(3):225-232. [Medline].
Parish JM, Lyng PJ, Wisbey J. Compliance with CPAP in elderly patients with OSA. Sleep Med. 2000 Jul 1. 1(3):209-214. [Medline].
Gozal D, Pope DW Jr. Snoring during early childhood and academic performance at ages thirteen to fourteen years. Pediatrics. 2001 Jun. 107(6):1394-9. [Medline].
Gozal D. Sleep-disordered breathing and school performance in children. Pediatrics. 1998 Sep. 102(3 Pt 1):616-20. [Medline].
Chervin RD, Clarke DF, Huffman JL, Szymanski E, Ruzicka DL, Miller V, et al. School performance, race, and other correlates of sleep-disordered breathing in children. Sleep Med. 2003 Jan. 4(1):21-7. [Medline].
Friedman BC, Hendeles-Amitai A, Kozminsky E, Leiberman A, Friger M, Tarasiuk A, et al. Adenotonsillectomy improves neurocognitive function in children with obstructive sleep apnea syndrome. Sleep. 2003 Dec 15. 26(8):999-1005. [Medline].
Chervin RD, Archbold KH. Hyperactivity and polysomnographic findings in children evaluated for sleep-disordered breathing. Sleep. 2001 May 1. 24(3):313-20. [Medline].
Chervin RD, Archbold KH, Dillon JE, Panahi P, Pituch KJ, Dahl RE, et al. Inattention, hyperactivity, and symptoms of sleep-disordered breathing. Pediatrics. 2002 Mar. 109(3):449-56. [Medline].
Keller DM. Childhood asthma raises risk for adult sleep apnea. Medscape Medical News. June 6, 2013. [Full Text].
Franklin KA, Holmgren PA, Jonsson F, Poromaa N, Stenlund H, Svanborg E. Snoring, pregnancy-induced hypertension, and growth retardation of the fetus. Chest. 2000 Jan. 117(1):137-41. [Medline].
Hartenbaum N, Collop N, Rosen IM, Phillips B, George CF, Rowley JA, et al. Sleep apnea and commercial motor vehicle operators: statement from the joint Task Force of the American College of Chest Physicians, American College of Occupational and Environmental Medicine, and the National Sleep Foundation. J Occup Environ Med. 2006 Sep. 48(9 Suppl):S4-37. [Medline].
Hartenbaum N, Collop N, Rosen IM, Phillips B, George CF, Rowley JA, et al. Sleep apnea and commercial motor vehicle operators: Statement from the joint task force of the American College of Chest Physicians, the American College of Occupational and Environmental Medicine, and the National Sleep Foundation. Chest. 2006 Sep. 130(3):902-5. [Medline].
Sansa G, Iranzo A, Santamaria J. Obstructive sleep apnea in narcolepsy. Sleep Med. 2010 Jan. 11(1):93-5. [Medline].
Anderson P. New Guideline for Sleep Apnea Diagnosis. Medscape Medical News. Available at http://www.medscape.com/viewarticle/829717#1. Accessed: August 13, 2014.
[Guideline] Qaseem A, Dallas P, Owens DK, et al. Diagnosis of Obstructive Sleep Apnea in Adults: A Clinical Practice Guideline From the American College of Physicians. Annals of Internal Medicine. Available at http://annals.org/article.aspx?articleid=1892620. Accessed: August 13, 2014.
Cintra F, Tufik S, D’Almeida V, Calegare BF, de Paola A, Oliveira W, et al. Cysteine: a potential biomarker for obstructive sleep apnea. Chest. 2011 Feb. 139(2):246-52. [Medline].
Flemons WW, Littner MR, Rowley JA, Gay P, Anderson WM, Hudgel DW, et al. Home diagnosis of sleep apnea: a systematic review of the literature. An evidence review cosponsored by the American Academy of Sleep Medicine, the American College of Chest Physicians, and the American Thoracic Society. Chest. 2003 Oct. 124(4):1543-79. [Medline].
Ahmed M, Patel NP, Rosen I. Portable monitors in the diagnosis of obstructive sleep apnea. Chest. 2007 Nov. 132(5):1672-7. [Medline].
Mulgrew AT, Fox N, Ayas NT, Ryan CF. Diagnosis and initial management of obstructive sleep apnea without polysomnography: a randomized validation study. Ann Intern Med. 2007 Feb 6. 146(3):157-66. [Medline].
Berry RB, Hill G, Thompson L, McLaurin V. Portable monitoring and autotitration versus polysomnography for the diagnosis and treatment of sleep apnea. Sleep. 2008 Oct 1. 31(10):1423-31. [Medline]. [Full Text].
Kuna ST, Gurubhagavatula I, Maislin G, et al. Noninferiority of functional outcome in ambulatory management of obstructive sleep apnea. Am J Respir Crit Care Med. 2011 May 1. 183(9):1238-44. [Medline].
Chai-Coetzer CL, Antic NA, Rowland LS, Catcheside PG, Esterman A, Reed RL, et al. A simplified model of screening questionnaire and home monitoring for obstructive sleep apnoea in primary care. Thorax. 2011 Mar. 66(3):213-9. [Medline].
Chai-Coetzer CL, Antic NA, Hamilton GS, McArdle N, Wong K, Yee BJ, et al. Physician Decision Making and Clinical Outcomes With Laboratory Polysomnography or Limited-Channel Sleep Studies for Obstructive Sleep Apnea: A Randomized Trial. Ann Intern Med. 2017 Jan 24. [Medline].
Parry NM. Home Sleep Testing as Good as Laboratory Testing for Apnea. Medscape Medical News. Available at http://www.medscape.com/viewarticle/874828?src=soc_tw_170125_mscpedt_news_pulm_sleepapnea#vp_1. January 23, 2017; Accessed: January 27, 2017.
Collop NA, Anderson WM, Boehlecke B, Claman D, Goldberg R, Gottlieb DJ, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 2007 Dec 15. 3(7):737-47. [Medline]. [Full Text].
Bonnet MH, Arand DL. Impact of motivation on Multiple Sleep Latency Test and Maintenance of Wakefulness Test measurements. J Clin Sleep Med. 2005 Oct 15. 1(4):386-90. [Medline].
Morgenthaler TI, Kapen S, Lee-Chiong T, Alessi C, Boehlecke B, Brown T, et al. Practice parameters for the medical therapy of obstructive sleep apnea. Sleep. 2006 Aug 1. 29(8):1031-5. [Medline].
[Guideline] Qaseem A, Holty JE, Owens DK, et al. Management of Obstructive Sleep Apnea in Adults: A Clinical Practice Guideline From the American College of Physicians. Annals of Internal Medicine. Available at http://annals.org/article.aspx?articleid=1742606. Accessed: August 13, 2014.
Kushida CA, Chediak A, Berry RB, Brown LK, Gozal D, Iber C, et al. Clinical guidelines for the manual titration of positive airway pressure in patients with obstructive sleep apnea. J Clin Sleep Med. 2008 Apr 15. 4(2):157-71. [Medline]. [Full Text].
Kushida CA, Littner MR, Hirshkowitz M, Morgenthaler TI, Alessi CA, Bailey D, et al. Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. Sleep. 2006 Mar 1. 29(3):375-80. [Medline].
Gay P, Weaver T, Loube D, Iber C. Evaluation of positive airway pressure treatment for sleep related breathing disorders in adults. Sleep. 2006 Mar 1. 29(3):381-401. [Medline].
Smith I, Lasserson TJ. Pressure modification for improving usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2009 Oct 7. CD003531. [Medline].
Vennelle M, White S, Riha RL, Mackay TW, Engleman HM, Douglas NJ. Randomized controlled trial of variable-pressure versus fixed-pressure continuous positive airway pressure (CPAP) treatment for patients with obstructive sleep apnea/hypopnea syndrome (OSAHS). Sleep. 2010 Feb 1. 33(2):267-71. [Medline]. [Full Text].
Morgenthaler TI, Aurora RN, Brown T, Zak R, Alessi C, Boehlecke B, et al. Practice parameters for the use of autotitrating continuous positive airway pressure devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome: an update for 2007. An American Academy of Sleep Medicine report. Sleep. 2008 Jan 1. 31(1):141-7. [Medline]. [Full Text].
Engleman HM, Martin SE, Deary IJ, Douglas NJ. Effect of continuous positive airway pressure treatment on daytime function in sleep apnoea/hypopnoea syndrome. Lancet. 1994 Mar 5. 343(8897):572-5. [Medline].
Engleman HM, Kingshott RN, Wraith PK, Mackay TW, Deary IJ, Douglas NJ. Randomized placebo-controlled crossover trial of continuous positive airway pressure for mild sleep Apnea/Hypopnea syndrome. Am J Respir Crit Care Med. 1999 Feb. 159(2):461-7. [Medline].
Sharma SK, Agrawal S, Damodaran D, Sreenivas V, Kadhiravan T, Lakshmy R, et al. CPAP for the metabolic syndrome in patients with obstructive sleep apnea. N Engl J Med. 2011 Dec 15. 365(24):2277-86. [Medline].
Bennett LS, Barbour C, Langford B, Stradling JR, Davies RJ. Health status in obstructive sleep apnea: relationship with sleep fragmentation and daytine sleepiness, and effects of continuous positive airway pressure treatment. Am J Respir Crit Care Med. 1999 Jun. 159(6):1884-90. [Medline].
Bahammam A, Delaive K, Ronald J, Manfreda J, Roos L, Kryger MH. Health care utilization in males with obstructive sleep apnea syndrome two years after diagnosis and treatment. Sleep. 1999 Sep 15. 22(6):740-7. [Medline].
Kohler M, Stoewhas AC, Ayers L, et al. Effects of Continuous Positive Airway Pressure Therapy Withdrawal in Patients with Obstructive Sleep Apnea: A Randomized Controlled Trial. Am. J. Respir. Crit. Care Med. November 2011. 184:
Crawford MR, Bartlett DJ, Coughlin SR, Phillips CL, Neill AM, Espie CA, et al. The effect of continuous positive airway pressure usage on sleepiness in obstructive sleep apnoea: real effects or expectation of benefit?. Thorax. 2012 May 26. [Medline].
Lin HS, Zuliani G, Amjad EH, Prasad AS, Badr MS, Pan CJ, et al. Treatment compliance in patients lost to follow-up after polysomnography. Otolaryngol Head Neck Surg. 2007 Feb. 136(2):236-40. [Medline].
Weaver TE, Maislin G, Dinges DF, Bloxham T, George CF, Greenberg H, et al. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep. 2007 Jun 1. 30(6):711-9. [Medline]. [Full Text].
Popescu G, Latham M, Allgar V, Elliott MW. Continuous positive airway pressure for sleep apnoea/hypopnoea syndrome: usefulness of a 2 week trial to identify factors associated with long term use. Thorax. 2001 Sep. 56(9):727-33. [Medline]. [Full Text].
Aloia MS, Arnedt JT, Stanchina M, Millman RP. How early in treatment is PAP adherence established? Revisiting night-to-night variability. Behav Sleep Med. 2007. 5(3):229-40. [Medline].
Aloia MS, Arnedt JT, Stepnowsky C, Hecht J, Borrelli B. Predicting treatment adherence in obstructive sleep apnea using principles of behavior change. J Clin Sleep Med. 2005 Oct 15. 1(4):346-53. [Medline].
McArdle N, Devereux G, Heidarnejad H, Engleman HM, Mackay TW, Douglas NJ. Long-term use of CPAP therapy for sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med. 1999 Apr. 159(4 Pt 1):1108-14. [Medline].
Platt AB, Kuna ST, Field SH, Chen Z, Gupta R, Roche DF, et al. Adherence to sleep apnea therapy and use of lipid-lowering drugs: a study of the healthy-user effect. Chest. 2010 Jan. 137(1):102-8. [Medline]. [Full Text].
Bakker JP, Marshall NS. Flexible pressure delivery modification of continuous positive airway pressure for obstructive sleep apnea does not improve compliance with therapy: Systematic review and meta-analysis. Chest. 2010 Dec 30. [Medline].
Collen J, Holley A, Lettieri C, Shah A, Roop S. The impact of split-night versus traditional sleep studies on CPAP compliance. Sleep Breath. 2010 Jun. 14(2):93-9. [Medline].
Chervin RD, Theut S, Bassetti C, Aldrich MS. Compliance with nasal CPAP can be improved by simple interventions. Sleep. 1997 Apr. 20(4):284-9. [Medline].
Massie CA, Hart RW, Peralez K, Richards GN. Effects of humidification on nasal symptoms and compliance in sleep apnea patients using continuous positive airway pressure. Chest. 1999 Aug. 116(2):403-8. [Medline].
Hoy CJ, Vennelle M, Kingshott RN, Engleman HM, Douglas NJ. Can intensive support improve continuous positive airway pressure use in patients with the sleep apnea/hypopnea syndrome?. Am J Respir Crit Care Med. 1999 Apr. 159(4 Pt 1):1096-100. [Medline].
Richards D, Bartlett DJ, Wong K, Malouff J, Grunstein RR. Increased adherence to CPAP with a group cognitive behavioral treatment intervention: a randomized trial. Sleep. 2007 May 1. 30(5):635-40. [Medline].
Likar LL, Panciera TM, Erickson AD, Rounds S. Group education sessions and compliance with nasal CPAP therapy. Chest. 1997 May. 111(5):1273-7. [Medline].
Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2009 Apr 15. CD007736. [Medline].
Fuchs FS, Pittarelli A, Hahn EG, Ficker JH. Adherence to continuous positive airway pressure therapy for obstructive sleep apnea: impact of patient education after a longer treatment period. Respiration. 2010. 80(1):32-7. [Medline].
Reeves-Hoche MK, Hudgel DW, Meck R, Witteman R, Ross A, Zwillich CW. Continuous versus bilevel positive airway pressure for obstructive sleep apnea. Am J Respir Crit Care Med. 1995 Feb. 151(2 Pt 1):443-9. [Medline].
Gay PC, Herold DL, Olson EJ. A randomized, double-blind clinical trial comparing continuous positive airway pressure with a novel bilevel pressure system for treatment of obstructive sleep apnea syndrome. Sleep. 2003 Nov 1. 26(7):864-9. [Medline].
Kushida CA, Morgenthaler TI, Littner MR, Alessi CA, Bailey D, Coleman J Jr, et al. Practice parameters for the treatment of snoring and Obstructive Sleep Apnea with oral appliances: an update for 2005. Sleep. 2006 Feb 1. 29(2):240-3. [Medline].
Ferguson KA, Cartwright R, Rogers R, Schmidt-Nowara W. Oral appliances for snoring and obstructive sleep apnea: a review. Sleep. 2006 Feb 1. 29(2):244-62. [Medline].
American Sleep Disorders Association. Practice parameters for the treatment of snoring and obstructive sleep apnea with oral appliances. American Sleep Disorders Association. Sleep. 1995 Jul. 18(6):511-3. [Medline].
Lazard DS, Blumen M, Levy P, Chauvin P, Fragny D, Buchet I, et al. The tongue-retaining device: efficacy and side effects in obstructive sleep apnea syndrome. J Clin Sleep Med. 2009 Oct 15. 5(5):431-8. [Medline]. [Full Text].
Engleman HM, McDonald JP, Graham D, Lello GE, Kingshott RN, Coleman EL, et al. Randomized crossover trial of two treatments for sleep apnea/hypopnea syndrome: continuous positive airway pressure and mandibular repositioning splint. Am J Respir Crit Care Med. 2002 Sep 15. 166(6):855-9. [Medline].
Phillips CL, Grunstein RR, Darendeliler MA, Mihailidou AS, Srinivasan VK, Yee BJ, et al. Health Outcomes of Continuous Positive Airway Pressure versus Oral Appliance Treatment for Obstructive Sleep Apnea. Am J Respir Crit Care Med. 2013 Apr 15. 187(8):879-87. [Medline].
Tsai WH, Vazquez JC, Oshima T, Dort L, Roycroft B, Lowe AA, et al. Remotely controlled mandibular positioner predicts efficacy of oral appliances in sleep apnea. Am J Respir Crit Care Med. 2004 Aug 15. 170(4):366-70. [Medline].
Raphaelson MA, Alpher EJ, Bakker KW, Perlstrom JR. Oral appliance therapy for obstructive sleep apnea syndrome: progressive mandibular advancement during polysomnography. Cranio. 1998 Jan. 16(1):44-50. [Medline].
Petelle B, Vincent G, Gagnadoux F, Rakotonanahary D, Meyer B, Fleury B. One-night mandibular advancement titration for obstructive sleep apnea syndrome: a pilot study. Am J Respir Crit Care Med. 2002 Apr 15. 165(8):1150-3. [Medline].
Phillips B. Upper airway surgery does not have a major role in the treatment of sleep apnea. J Clin Sleep Med. 2005. 1:241-5.
Powell N. Upper airway surgery does have a major role in the treatment of obstructive sleep apnea “the tail end of the dog”. Pro. J Clin Sleep Med. 2005 Jul 15. 1(3):236-40. [Medline].
Sher AE. Upper airway surgery for obstructive sleep apnea. Sleep Med Rev. 2002 Jun. 6(3):195-212. [Medline].
Sher AE, Schechtman KB, Piccirillo JF. The efficacy of surgical modifications of the upper airway in adults with obstructive sleep apnea syndrome. Sleep. 1996 Feb. 19(2):156-77. [Medline].
Li KK, Powell NB, Riley RW, Troell R, Guilleminault C. Overview of phase I surgery for obstructive sleep apnea syndrome. Ear Nose Throat J. 1999 Nov. 78(11):836-7, 841-5. [Medline].
Li KK, Riley RW, Powell NB, Troell R, Guilleminault C. Overview of phase II surgery for obstructive sleep apnea syndrome. Ear Nose Throat J. 1999 Nov. 78(11):851, 854-7. [Medline].
Powell NB, Riley RW, Troell RJ, Li K, Blumen MB, Guilleminault C. Radiofrequency volumetric tissue reduction of the palate in subjects with sleep-disordered breathing. Chest. 1998 May. 113(5):1163-74. [Medline].
Li KK, Powell NB, Riley RW, Troell RJ, Guilleminault C. Radiofrequency volumetric reduction of the palate: An extended follow-up study. Otolaryngol Head Neck Surg. 2000 Mar. 122(3):410-4. [Medline].
Coleman SC, Smith TL. Midline radiofrequency tissue reduction of the palate for bothersome snoring and sleep-disordered breathing: A clinical trial. Otolaryngol Head Neck Surg. 2000 Mar. 122(3):387-94. [Medline].
Grunstein RR, Stenlof K, Hedner JA, Peltonen M, Karason K, Sjostrom L. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. Sleep. 2007 Jun 1. 30(6):703-10. [Medline]. [Full Text].
[Guideline] Epstein LJ, Kristo D, Strollo PJ Jr, Friedman N, Malhotra A, Patil SP, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009 Jun 15. 5(3):263-76. [Medline]. [Full Text].
[Guideline] SAGES guideline for clinical application of laparoscopic bariatric surgery. Surg Obes Relat Dis. 2009 May-Jun. 5(3):387-405. [Medline].
[Guideline] Schumann R, Jones SB, Cooper B, Kelley SD, Bosch MV, Ortiz VE, et al. Update on best practice recommendations for anesthetic perioperative care and pain management in weight loss surgery, 2004-2007. Obesity (Silver Spring). 2009 May. 17(5):889-94. [Medline].
Woodson BT, Steward DL, Weaver EM, Javaheri S. A randomized trial of temperature-controlled radiofrequency, continuous positive airway pressure, and placebo for obstructive sleep apnea syndrome. Otolaryngol Head Neck Surg. 2003 Jun. 128(6):848-61. [Medline].
Weaver EM, Maynard C, Yueh B. Survival of veterans with sleep apnea: continuous positive airway pressure versus surgery. Otolaryngol Head Neck Surg. 2004 Jun. 130(6):659-65. [Medline].
Walker-Engstrom ML, Tegelberg A, Wilhelmsson B, Ringqvist I. 4-year follow-up of treatment with dental appliance or uvulopalatopharyngoplasty in patients with obstructive sleep apnea: a randomized study. Chest. 2002 Mar. 121(3):739-46. [Medline].
Guilleminault C, Philip P. Tiredness and somnolence despite initial treatment of obstructive sleep apnea syndrome (what to do when an OSAS patient stays hypersomnolent despite treatment). Sleep. 1996 Nov. 19(9 Suppl):S117-22. [Medline].
Roizenblatt S, Guilleminault C, Poyares D, Cintra F, Kauati A, Tufik S. A double-blind, placebo-controlled, crossover study of sildenafil in obstructive sleep apnea. Arch Intern Med. 2006 Sep 18. 166(16):1763-7. [Medline].
Kingshott RN, Vennelle M, Coleman EL, Engleman HM, Mackay TW, Douglas NJ. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med. 2001 Mar. 163(4):918-23. [Medline].
Pack AI, Black JE, Schwartz JR, Matheson JK. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med. 2001 Nov 1. 164(9):1675-81. [Medline].
Schwartz JR, Hirshkowitz M, Erman MK, Schmidt-Nowara W. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. Chest. 2003 Dec. 124(6):2192-9. [Medline].
Kuna ST, Gurubhagavatula I, Maislin G, et al. Non-inferiority of Functional Outcome in Ambulatory Management of Obstructive Sleep Apnea. Resp & Crit Care Med. Jan 20, 2011.
Veasey SC, Guilleminault C, Strohl KP, Sanders MH, Ballard RD, Magalang UJ. Medical therapy for obstructive sleep apnea: a review by the Medical Therapy for Obstructive Sleep Apnea Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep. 2006 Aug 1. 29(8):1036-44. [Medline].
Brooks M. Disposable Skin Patch Detects Sleep Apnea at Home. Medscape News & Perspective. Available at https://www.medscape.com/viewarticle/881212. June 6, 2017; Accessed: January 10, 2018.
SLEEP 2017. 31st Annual Meeting of the Associated Professional Sleep Societies. Presented June 5, 2017. Abstract 0448:
Himanshu Wickramasinghe, MD, MBBS Attending Physician, Pulmonary, Critical Care, and Sleep Medicine, Henry Mayo Newhall Memorial Hospital
Disclosure: Nothing to disclose.
James A Rowley, MD Professor, Fellowship Program Director, Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Wayne State University School of Medicine
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Daniel R Ouellette, MD, FCCP Associate Professor of Medicine, Wayne State University School of Medicine; Chair of the Clinical Competency Committee, Pulmonary and Critical Care Fellowship Program, Senior Staff and Attending Physician, Division of Pulmonary and Critical Care Medicine, Henry Ford Health System; Chair, Guideline Oversight Committee, American College of Chest Physicians
Disclosure: Nothing to disclose.
Zab Mosenifar, MD, FACP, FCCP Geri and Richard Brawerman Chair in Pulmonary and Critical Care Medicine, Professor and Executive Vice Chairman, Department of Medicine, Medical Director, Women’s Guild Lung Institute, Cedars Sinai Medical Center, University of California, Los Angeles, David Geffen School of Medicine
Zab Mosenifar, MD, FACP, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, American Thoracic Society
Disclosure: Nothing to disclose.
Ralph Downey, III, PhD Staff Sleep Specialist, Cleveland Clinic Foundation; Associate Clinical Professor of Medicine, Loma Linda University School of Medicine
Ralph Downey, III, PhD is a member of the following medical societies: American Academy of Sleep Medicine
Disclosure: Nothing to disclose.
Sat Sharma, MD, FRCPC Professor and Head, Division of Pulmonary Medicine, Department of Internal Medicine, University of Manitoba Faculty of Medicine; Site Director, Respiratory Medicine, St Boniface General Hospital, Canada
Sat Sharma, MD, FRCPC is a member of the following medical societies: American Academy of Sleep Medicine, American College of Chest Physicians, American College of Physicians-American Society of Internal Medicine, American Thoracic Society, Canadian Medical Association, Royal College of Physicians and Surgeons of Canada, Royal Society of Medicine, Society of Critical Care Medicine, World Medical Association
Disclosure: Nothing to disclose.
Philip M Gold, MD Professor of Medicine, Chief of Pulmonary and Critical Care Medicine, Medical Director of Respiratory Care, Loma Linda University Medical Center
Philip M Gold, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Heart Association, American Lung Association, American Medical Association, American Thoracic Society, California Medical Association, Society of Critical Care Medicine, Undersea and Hyperbaric Medical Society, California Thoracic Society, American Federation for Clinical Research, Association of Subspecialty Professors
Disclosure: Nothing to disclose.
Obstructive Sleep Apnea (OSA)
Research & References of Obstructive Sleep Apnea (OSA)|A&C Accounting And Tax Services